1. HeitJA, CohenAT, AndersonFAJr (2005) on behalf of the VTE Impact Assessment Group (2005) Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. ASH Annual Meeting Abstracts 106: 910.
2. HeitJA, O'FallonWM, PettersonTM, LohseCM, SilversteinMD, et al. (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162: 1245–1248.
3. SorensenHT, MellemkjaerL, OlsenJH, BaronJA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343: 1846–1850.
4. KohlerBA, WardE, McCarthyBJ, SchymuraMJ, RiesLAG, et al. (2011) Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Canc Inst 103: 714–736.
5. VincentGK, VelkoffVA (2010) The next four decades—the older population in the United States: 2010 to 2050. Population estimates and projections. Washington (District of Columbia): US Census Bureau.
6. HeitJA, SilversteinMD, MohrDN, PettersonTM, O'FallonWM, et al. (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160: 809–815.
7. WhiteRH, ZhouH, RomanoPS (2003) Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 90: 446–455.
8. KhoranaAA, ConnollyGC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27: 4839–4847.
9. LymanGH, KhoranaAA, FalangaA, Clarke-PearsonD, FlowersC, et al. (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25: 5490–5505.
10. MandalàM, FalangaA, PiccioliA, PrandoniP, PoglianiEM, et al. (2006) Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hemat 59: 194–204.
11. KahnSR, LimW, DunnAS, CushmanM, DentaliF, et al. (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141: e195S–e226S.
12. StreiffMB, BockenstedtPL, CatalandSR, ChesneyC, EbyC, et al. (2011) Venous thromboembolic disease. J Natl Compr Canc Netw 9: 714–777.
13. KhoranaAA, FrancisCW, CulakovaE, KudererNM, LymanGH (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110: 2339–2346.
14. LevitanN, DowlatiA, RemickSC, TahsildarHI, SivinskiLD, et al. (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78: 285–291.
15. SteinPD, BeemathA, MeyersFA, SkafE, SanchezJ, et al. (2006) Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119: 60–68.
16. MoherD, LiberatiA, TetzlaffJ, AltmanDG, ThePG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097 doi:10.1371/journal.pmed.1000097.
17. SatarianoWA, SillimanRA (2003) Comorbidity: implications for research and practice in geriatric oncology. Crit Rev Oncol Hemat 48: 239–248.
18. Cancer Research UK (2012) January 27 Cancer incidence—UK statistics [database]. Available: http://info.cancerresearchuk.org/cancerstats/incidence/. Accessed 28 March 2012.
19. KhoranaAA, FrancisCW, CulakovaE, LymanGH (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104: 2822–2829.
20. AyC, VormittagR, DunklerD, SimanekR, ChiriacA-L, et al. (2009) D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27: 4124–4129.
21. SuttonAJ, AbramsKR, JonesDR, SheldonTA, SongF (2000) Methods for meta-analysis in medical research. Chichester (United Kingdom): Wiley.
22. HigginsJPT, ThompsonSG, DeeksJJ, AltmanDG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
23. Abdel-RazeqHN, HijjawiSB, JalladSG, AbabnehBA (2010) Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience. J Thromb Thrombolysis 30: 286–293.
24. AlcalayA, WunT, KhatriV, ChewHK, HarveyD, et al. (2006) Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 24: 1112–1118.
25. AndtbackaRHI, BabieraG, SingletarySE, HuntKK, Meric-BernstamF, et al. (2006) Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 243: 96–101.
26. AraiY, EgawaS, TobisuK, SagiyamaK, SumiyoshiY, et al. (2000) Radical retropubic prostatectomy: time trends, morbidity and mortality in Japan. BJU Int 85: 287–294.
27. AugusteKI, Quinones-HinojosaA, GadkaryC, ZadaG, LambornKR, et al. (2003) Incidence of venous thromboembolism in patients undergoing craniotomy and motor mapping for glioma without intraoperative mechanical prophylaxis to the contralateral leg. J Neurosurg 99: 680–684.
28. BlomJW, OsantoS, RosendaalFR (2004) The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2: 1760–1765.
29. BlomJW, OsantoS, RosendaalFR (2006) High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer 42: 410–414.
30. BlomJW, VanderschootJPM, OostindierMJ, OsantoS, van der MeerFJM, et al. (2006) Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4: 529–535.
31. BrandesAA, ScelziE, SalmistraroG, ErmaniM, CarolloC, et al. (1997) Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer 33: 1592–1596.
32. ChewHK, DaviesAM, WunT, HarveyD, ZhouH, et al. (2008) The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 6: 601–608.
33. ChewHK, WunT, HarveyD, ZhouH, WhiteRH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166: 458–464.
34. ChewHK, WunT, HarveyDJ, ZhouH, WhiteRH (2007) Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 25: 70–76.
35. ConnollyGC, KhoranaAA, KudererNM, CulakovaE, FrancisCW, et al. (2010) Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 126: 113–118.
36. Cronin-FentonDP, SondergaardF, PedersenLA, FryzekJP, CetinK, et al. (2010) Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer 103: 947–953.
37. De StefanoV, SoraF, RossiE, ChiusoloP, LaurentiL, et al. (2005) The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 3: 1985–1992.
38. Di NisioM, FerranteN, De TursiM, IacobelliS, CuccurulloF, et al. (2010) Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 104: 1049–1054.
39. HallIE, AndersenMS, KrumholzHM, GrossCP (2009) Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol 2009: 182521 doi:10.1155/2009/182521.
40. HernandezRK, SorensenHT, PedersenL, JacobsenJ, LashTL (2009) Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 115: 4442–4449.
41. KanzR, VukovichT, VormittagR, DunklerD, AyC, et al. (2011) Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 9: 57–63.
42. KaufmanJL, NookaA, VranaM, GleasonC, HeffnerLT, et al. (2010) Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer 116: 3143–3151.
43. KirwanCC, McDowellG, McCollumCN, KumarS, ByrneGJ (2008) Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer 99: 1000–1006.
44. KomrokjiRS, UppalNP, KhoranaAA, LymanGH, KaplanKL, et al. (2006) Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 47: 1029–1033.
45. KuGH, WhiteRH, ChewHK, HarveyDJ, ZhouH, et al. (2009) Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 113: 3911–3917.
46. MandalaM, BarniS, PrinsM, LabiancaR, TondiniC, et al. (2010) Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 21: 871–876.
47. MasonDP, QuaderMA, BlackstoneEH, RajeswaranJ, DeCampMM, et al. (2006) Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. J Thorac Cardiovasc Surg 131: 711–718.
48. NegaardHFS, IversenPO, OstenstadB, IversenN, HolmePA, et al. (2008) Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost 99: 1040–1048.
49. NumicoG, GarroneO, DongiovanniV, SilvestrisN, ColantonioI, et al. (2005) Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 103: 994–999.
50. OhSY, KimJH, LeeK-W, BangS-M, HwangJ-H, et al. (2008) Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. Thromb Res 122: 485–490.
51. OttenH-MMB, MathijssenJ, ten CateH, SoesanM, InghelsM, et al. (2004) Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 164: 190–194.
52. PorukKE, FirpoMA, HuerterLM, ScaifeCL, EmersonLL, et al. (2010) Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 19: 2605–2610.
53. ReevesD, LiuCY (2010) Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population. J Oncol Pharm Pract 16: 27–31.
54. SallahS, WanJY, NguyenNP (2002) Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87: 575–579.
55. SecinFP, JibornT, BjartellAS, FournierG, SalomonL, et al. (2008) Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol 53: 134–145.
56. SemradTJ, O'DonnellR, WunT, ChewH, HarveyD, et al. (2007) Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106: 601–608.
57. SgarabottoD, PrandoniP, StefaniPM, ScanoF, VianelloF, et al. (1998) Prevalence and patterns of symptomatic thromboembolism in oncohematology. Haematologica 83: 442–446.
58. SimanekR, VormittagR, HasslerM, RoesslerK, SchwarzM, et al. (2007) Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 9: 89–95.
59. StreiffMB, SegalJ, GrossmanSA, KicklerTS, WeirEG (2004) ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 100: 1717–1723.
60. TagalakisV, LeviD, AgulnikJS, CohenV, KasymjanovaG, et al. (2007) High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients. J Thorac Oncol 2: 729–734.
61. Van HemelrijckM, AdolfssonJ, GarmoH, Bill-AxelsonA, BrattO, et al. (2010) Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol 11: 450–458.
62. VormittagR, SimanekR, AyC, DunklerD, QuehenbergerP, et al. (2009) High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 29: 2176–2181.
63. WederW, CollaudS, EberhardtWEE, HillingerS, WelterS, et al. (2010) Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 139: 1424–1430.
64. WhittleAM, AllsupDJ, BaileyJR (2011) Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism. Leuk Res 35: 419–421.
65. ZecchinaG, GhioP, BosioS, CravinoM, CamaschellaC, et al. (2007) Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. Clin Lung Cancer 8: 264–267.
66. ZhouX, TeegalaS, HuenA, JiY, FayadL, et al. (2010) Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med 123: 935–941.
67. CherukuR, TapazoglouE, EnsleyJ, KishJA, CummingsGD, et al. (1991) The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 68: 2621–2624.
68. ClarkeCS, OtridgeBW, CarneyDN (1990) Thromboembolism. A complication of weekly chemotherapy in the treatment of non-Hodgkin's lymphoma. Cancer 66: 2027–2030.
69. DentaliF, MalatoA, AgenoW, ImperatoriA, CajozzoM, et al. (2008) Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. J Thorac Cardiovasc Surg 135: 705–706.
70. DhamiMS, BonaRD, CalogeroJA, HellmanRM (1993) Venous thromboembolism and high grade gliomas. Thromb Haemost 70: 393–396.
71. HershmanDL, BuonoDL, MalinJ, McBrideR, TsaiWY, et al. (2009) Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 101: 1633–1641.
72. HoyJ, NeemanT, Stuart-HarrisR, DavisA (2009) Risk of venous thromboembolism in patients receiving adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide for early breast cancer. Asia Pac J Clin Oncol 5: 129–136.
73. ImbertiD, VallisaD, AnselmiE, MoroniCF, BerteR, et al. (2004) Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia. Tumori 90: 390–393.
74. IversenLH, OkholmM, Thorlacius-UssingO (1996) Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease—a preliminary study. Thromb Haemost 76: 523–528.
75. LernerSE, BluteML, LieberMM, ZinckeH (1995) Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. Oncology (Williston) 9: 379–389.
76. MandalaM, FalangaA, CremonesiM, ZaccanelliM, FlorianiI, et al. (2006) The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma. Thromb Haemost 95: 752–754.
77. MitchellSY, LingardEA, KestevenP, McCaskieAW, GerrandCH (2007) Venous thromboembolism in patients with primary bone or soft-tissue sarcomas. J Bone Joint Surg Am 89: 2433–2439.
78. RoddyJVF, PartridgeSM, RockeyML, PruemerJM, GuoJJ, et al. (2010) Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents. Am J Clin Oncol 33: 36–42.
79. RuggieriP, MontaltiM, PalaE, AngeliniA, CalabroT, et al. (2010) Clinically significant thromboembolic disease in orthopedic oncology: an analysis of 986 patients treated with low-molecular-weight heparin. J Surg Oncol 102: 375–379.
80. SantosFPS, AlvaradoY, KantarjianH, VermaD, O'BrienS, et al. (2011) Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 117: 982–991.
81. SeifterEJ, YoungRC, LongoDL (1985) Deep venous thrombosis during therapy for Hodgkin's disease. Cancer Treat Rep 69: 1011–1013.
82. SilvaniA, SalmaggiA, EoliM, LampertiE, BoiardiA (2003) Venous thromboembolism in malignant glioma patients treated by chemoradiotherapy. Neurol Sci 24: 272.
83. ZinckeH, OesterlingJE, BluteML, BergstralhEJ, MyersRP, et al. (1994) Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152: 1850–1857.
84. RodriguesC, FerrarottoR, FilhoR, NovisY, HoffP (2010) Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis 30: 67–78.
85. EadenJA, AbramsKR, MayberryJF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526–535.
86. ThomasT, AbramsKA, RobinsonRJ, MayberryJF (2007) Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Alimen Pharm Ther 25: 657–668.
87. BlomJW, DoggenCJM, OsantoS, RosendaalFR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293: 715–722.
88. CohenAT, DavidsonBL, GallusAS, LassenMR, PrinsMH, et al. (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332: 325–329.
89. MismettiP, Laporte-SimitsidisS, TardyB, CucheratM, BuchmullerA, et al. (2000) Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 83: 14–19.
90. LevineM, HirshJ, GentM, ArnoldA, WarrD, et al. (1994) Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage-IV breast-cancer. Lancet 343: 886–889.
91. MeyerG, MarjanovicZ, ValckeJ, LorcerieB, GruelY, et al. (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162: 1729–1735.
92. PrandoniP, LensingAWA, PiccioliA, BernardiE, SimioniP, et al. (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100: 3484–3488.